ScholarLens Back to search
2016•Clinical Pulmonary MedicineRequires access

The Safety of Fluticasone-Salmeterol in Patients With Moderate to Severe Asthma

Cristobal Risquez, Dana Zappetti

Open publisher page 1 citations

Abstract

Synopsis: The AUSTRi trial evaluated the safety of combination fluticisone-salmeterol in moderate to severe asthma, and this medication was found to be noninferior to fluticasone alone. This is an important first study in validating the use of this medication in asthmatic patients after earlier controversial studies suggested the risk of routinely adding long-acting β-agonists to the management of asthma patients. Source: Stempel, DA, Raphiou IH, Kral KM, et al. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone. N Engl J Med. 2016;374(19):1822–1830.

About this research paper

What this paper is about

Synopsis: The AUSTRi trial evaluated the safety of combination fluticisone-salmeterol in moderate to severe asthma, and this medication was found to be noninferior to fluticasone alone. This is an important first study in validating the use of this medication in asthmatic patients after earlier controversial studies suggested the risk of routinely adding long-acting β-agonists to the management of asthma patients. Source: Stempel, DA, Raphiou IH, Kral KM, et al. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone. N Engl J Med. 2016;374(19):1822–1830.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Synopsis: The AUSTRi trial evaluated the safety of combination fluticisone-salmeterol in moderate to severe asthma, and this medication was found to be noninferior to fluticasone alone. This is an important first study in validating the use of this medication in asthmatic patients after earlier controversial studies suggested the risk of routinely adding long-acting β-agonists to the management of asthma patients. Source: Stempel, DA, Raphiou IH, Kral KM, et al. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone. N Engl J Med. 2016;374(19):1822–1830.

Key concepts: Salmeterol, Medicine, Fluticasone, Asthma, Adverse effect, Anesthesia, Internal medicine

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
The Safety of Fluticasone-Salmeterol in Patients With Moderate to Severe Asthma — Research Paper | ScholarLens